PUSEM PATİR, NUR SOYER, ISABEL RAİKA DURUSOY, FAHRİ SAHİN, GURAY SAYDAM, MAHMUT TOBU, MURAT TOMBULOGLU, FİLİZ VURAL
Experimental and Clinical Transplantation - 2025;23(4):299-305
Objectives: The aim of our study was to evaluate the efficacy and toxicity of TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) and BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimens before autologous hematopoietic stem cell transplant in patients with lymphoma. Materials and Methods: We retrospectively analyzed 108 relapsed/refractory lymphoma patients who had high-dose treatments followed by autologous hema¬topoietic stem cell transplant between October 2012 and February 2017. Results: At a median follow-up period of 16 months, the estimated 2-year progression-free survival rates for the TECAM and BEAM groups were 55.7% and 52.9%, respectively (P = .811). The estimated 2-year overall survival rate in the TECAM group (55.9%) was relatively inferior to that shown in the BEAM group (67%), but the differences were not significant (P = .238). No differences were observed for time to hematopoietic recovery and duration of hospitalization. Incidences of transplant-related infectious and noninfectious com¬plications were similar for each conditioning regimen. Conclusions: Our experience shows that the TECAM regimen is an effective high-dose chemotherapy for lymphoma patients before autologous hematopoietic stem cell transplant.
